全文获取类型
收费全文 | 10344篇 |
免费 | 746篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 77篇 |
儿科学 | 295篇 |
妇产科学 | 293篇 |
基础医学 | 1398篇 |
口腔科学 | 234篇 |
临床医学 | 1276篇 |
内科学 | 2064篇 |
皮肤病学 | 265篇 |
神经病学 | 1081篇 |
特种医学 | 188篇 |
外科学 | 918篇 |
综合类 | 67篇 |
一般理论 | 16篇 |
预防医学 | 1314篇 |
眼科学 | 182篇 |
药学 | 682篇 |
中国医学 | 32篇 |
肿瘤学 | 745篇 |
出版年
2024年 | 16篇 |
2023年 | 132篇 |
2022年 | 226篇 |
2021年 | 462篇 |
2020年 | 264篇 |
2019年 | 360篇 |
2018年 | 377篇 |
2017年 | 276篇 |
2016年 | 316篇 |
2015年 | 322篇 |
2014年 | 397篇 |
2013年 | 584篇 |
2012年 | 832篇 |
2011年 | 830篇 |
2010年 | 475篇 |
2009年 | 377篇 |
2008年 | 635篇 |
2007年 | 629篇 |
2006年 | 572篇 |
2005年 | 548篇 |
2004年 | 456篇 |
2003年 | 442篇 |
2002年 | 395篇 |
2001年 | 47篇 |
2000年 | 40篇 |
1999年 | 40篇 |
1998年 | 69篇 |
1997年 | 70篇 |
1996年 | 62篇 |
1995年 | 53篇 |
1994年 | 40篇 |
1993年 | 45篇 |
1992年 | 33篇 |
1991年 | 31篇 |
1990年 | 28篇 |
1989年 | 26篇 |
1988年 | 29篇 |
1987年 | 28篇 |
1986年 | 25篇 |
1985年 | 26篇 |
1984年 | 33篇 |
1983年 | 39篇 |
1982年 | 35篇 |
1981年 | 35篇 |
1980年 | 41篇 |
1979年 | 14篇 |
1978年 | 17篇 |
1977年 | 18篇 |
1975年 | 14篇 |
1973年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Alice Nourissat MD Isabelle Bairati MD PhD Elodie Samson MSc André Fortin MD MSc Michel Gélinas MD Abdenour Nabid MD François Brochet MD Bernard Têtu MD François Meyer MD DSc 《Cancer》2010,116(9):2275-2283
BACKGROUND:
The purpose of the study was to identify predictors of weight loss during radiotherapy (RT) in patients with stage I or II head and neck (HN) cancer.METHODS:
This study was conducted as part of a phase 3 chemoprevention trial. A total of 540 patients were randomized. The patients were weighed before and after RT. Their baseline characteristics, including lifestyle habits, diet, and quality of life, were assessed as potential predictors. Predictors were identified using multiple linear regressions. The reliability of the model was assessed by bootstrap resampling. A receiver operating characteristics curve was generated to estimate the model's accuracy in predicting critical weight loss (≥5%).RESULTS:
The mean weight loss was 2.2 kg (standard deviation, 3.4). Five factors were associated with a greater weight loss: all HN cancer sites other than the glottic larynx (P<.001), higher pre‐RT body weight (P<.001), stage II disease (P = .002), dysphagia and/or odynophagia before RT (P = .001), and a lower Karnofsky performance score (P = .028). There was no association with pre‐RT lifestyle habits, diet, or quality of life. The bootstrapping method confirmed the reliability of this predictive model. The area under the curve was 71.3% (95% confidence interval, 65.8‐76.9), which represents an acceptable ability of the model to predict critical weight loss.CONCLUSIONS:
These results could be useful to clinicians for screening patients with early stage HN cancer treated by RT who require special nutritional attention. Cancer 2010. © 2010 American Cancer Society. 相似文献62.
63.
Lalidia Bruno Ouoba Lamouni Habibata-Zerbo Bianca Zecchin Giacomo Barbierato Sandaogo Hamidou-Ouandaogo Elisa Palumbo Edoardo Giussani Alessio Bortolami Mamadou Niang Adele Traore-Kam Calogero Terregino Maritou Guitti-Kindo Angelique Angot Dominique Guigma Nicolas Barro Alice Fusaro Isabella Monne 《Viruses》2022,14(9)
Since 2006, the poultry population in Burkina Faso has been seriously hit by different waves of Highly Pathogenic Avian Influenza (HPAI) H5N1 epizootics. In December 2021, three distinct regions of Burkina Faso, namely, Gomboussougou, Bonyollo, and Koubri, detected HPAI H5N1 viruses in poultry. Whole genome characterization and statistical phylogenetic approaches were applied to shed light on the potential origin of these viruses and estimate the time of virus emergence. Our results revealed that the HPAI H5N1 viruses reported in the three affected regions of Burkina Faso cluster together within clade 2.3.4.4b, and are closely related to HPAI H5N1 viruses identified in Nigeria and Niger in the period 2021–2022, except for the PA gene, which clusters with H9N2 viruses of the zoonotic G1 lineage collected in West Africa between 2017 and 2020. These reassortant viruses possess several mutations that may be associated with an increased zoonotic potential. Although it is difficult to ascertain where and when the reassortment event occurred, the emergence of a H5N1/H9N2 reassortant virus in a vulnerable region, such as West Africa, raises concerns about its possible impact on animal and human health. These findings also highlight the risk that West Africa may become a new hotspot for the emergence of new genotypes of HPAI viruses. 相似文献
64.
Ludovica Pasca Alice Gardani Matteo Paoletti Daniele Velardo Angela Berardinelli 《Acta myologica》2022,41(3):121
Duchenne muscular dystrophy (DMD) is a severe, progressive X-linked recessive disorder, caused by the absence of the dystrophin protein. A resolutive therapy for DMD is not yet available. The first approved drug for DMD patients with nonsense mutations is ataluren, approved for the treatment of children aged ≥ 2 yrs, that seems effective in slowing the disease progression. An earlier introduction of ataluren seems to give better results.We report the case of a 14-year-old DMD patient with a nonsense mutation in exon 70, still ambulant, who started taking ataluren at 12 years and remained stable for the following two years. The patient was on steroid since the age of 6, with beneficial effects. At two-years follow-up, an optimal disease evolution was observed, associated with a constant decrease of creatine kinase blood levels. Despite the late start of the treatment, ataluren seems to have significantly contributed to the stabilization of the functional status in this patient though it cannot be excluded that the result may have been influenced by the previous favorable course of the disease. However, further studies should be planned in patients with similar age treated with ataluren to better evaluate the treatment’s results compared to the natural course of the disease.Key words: Duchenne muscular dystrophy, target therapy, nonsense mutation, ataluren, time function tests 相似文献
65.
66.
Dixon B. Kaufman George W. Burke III David S. Bruce Christopher P. Johnson A. Osama Gaber David E. R. Sutherland Robert M. Merion Scott A. Gruber Eugene Schweitzer John P. Leone Christopher L. Marsh Edward Alfrey Waldo Concepcion Mark D. Stegall James A. Schulak Paul F. Gores Enrico Benedetti Craig Smith Alice K. Henning Fernando Kuehnel Sarah King William E. Fitzsimmons 《American journal of transplantation》2003,3(7):855-864
A randomized, multicenter, prospective study was conducted at 18 pancreas transplant centers in the United States to determine the role of induction therapy in simultaneous pancreas-kidney (SPK) transplantation. One hundred and 74 recipients were enrolled: 87 recipients each in the induction and noninduction treatment arms. Maintenance immunosuppression consisted of tacrolimus, mycophenolate mofetil, and corticosteroids. There were no statistically significant differences between treatment groups for patient, kidney, and pancreas graft survival at 1-year. The 1-year cumulative incidence of any treated biopsy-confirmed or presumptive rejection episodes (kidney or pancreas) in the induction and noninduction treatment arms was 24.6% and 31.2% (p = 0.28), respectively. The 1-year cumulative incidence of biopsy-confirmed, treated, acute kidney allograft rejection in the induction and noninduction treatment arms was 13.1% and 23.0% (p = 0.08), respectively. Biopsy-confirmed kidney allograft rejection occurred later post-transplant and appeared to be less severe among recipients that received induction therapy. The highest rate of Cytomegalovirus (CMV) viremia/syndrome was observed in the subgroup of recipients who received T-cell depleting antibody induction and received organs from CMV serologically positive donors. Decisions regarding the routine use of induction therapy in SPK transplantation must take into consideration its differential effects on risk of rejection and infection. 相似文献
67.
Laura Oggianu Giorgio Di Dato Giorgina Mangano Maria Teresa Rosignoli Savannah McFeely Alice Ban Ke Hannah M. Jones Alessandro Comandini 《CTS Clinical and Translational Science》2022,15(6):1417
Trazodone is approved for the treatment of major depressive disorders, marketed as immediate release (IR), prolonged release, and once a day (OAD) formulation. The different formulations allow different administration schedules and may be useful to facilitate patients’ compliance to the antidepressant treatment. A previously verified physiologically‐based pharmacokinetic model based on in vitro and in vivo information on trazodone pharmacokinetics was applied, aiming at predicting brain receptor occupancy (RO) after single and repeated dosing of the IR formulation and repeated dosing of the OAD formulation in healthy subjects. Receptors included in the simulations were selected using static calculations of RO based on the maximum unbound brain concentration (Cmax,brain,u) of trazodone for each formulation and dosing scheme, resulting in 16 receptors being simulated. Seven receptors were simulated for the IR low dose formulation (30 mg), with similar t onset and duration of coverage (range: 0.09–0.25 h and 2.1–>24 h, respectively) as well as RO (range: 0.64–0.92) predicted between day 1 and day 7 of dosing. The 16 receptors evaluated for the OAD formulation (300 mg) showed high RO (range: 0.97–0.84 for the receptors also covered by the IR formulation and 0.73–0.48 for the remaining) correlating with affinity and similar duration of time above the target threshold to the IR formulation (range: 2–>24 h). The dose‐dependent receptor coverage supports the multimodal activity of trazodone, which may further contribute to its fast antidepressant action and effectiveness in controlling different symptoms in depressed patients. Study Highlights
- WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
- WHAT QUESTION DID THIS STUDY ADDRESS?
- WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
- HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
68.
Daniela N Amora Ticiana M Sousa Alice M C Martins Paulo S F Barbosa Marta R Magalh?es Marcus H Toyama Manassés C Fonteles Dalgimar B de Menezes Helena S A Monteiro 《Toxicon》2006,47(3):260-264
Ophidian accidents caused by the subspecies Crotalus durissus are responsible for high morbity and mortality rates. Acute renal failure is a common complication observed in these accidents. The aim of the present study was to investigate the renal effects promoted by the venom of C. d. collilineatus and its fractions, crotoxin and phospholipase A2. C. d. collilineatus (Cdc; 30 microg mL(-1)), crotoxin (CTX; 10 microg mL(-1)) and phospholipase A2 (PLA2; 10 microg mL(-1)) were tested in isolated rat kidney. The first 30 min of each experiment were used as an internal control and Cdc or its fractions, CTX and PLA2 were added to the system after this period. All experiments lasted 120 min. The venom of Cdc decreased perfusion pressure (PP; control120 = 110.3 +/- 3.69 mmHg; Cdc120 = 96.7+/-8.1 mmHg), renal vascular resistance (RVR; control120 = 6.42+/-0.78 mmHg mL g(-1) min(-1); Cdc120 = 4.8+/-0.56 mmHg/mL g(-1) min(-1)), urinary flow (UF; control120 = 0.19+/-0.03 mL g(-1) min(-1); Cdc120 = 0.12 +/- 0.01 mL g(-1) min(-1)), and glomerular filtration rate (GFR; control120 = 0.79 +/- 0.07 mL g(-1) min(-1); Cdc120 = 0.53 +/- 0.09 mL g(-1) min(-1)), but had no effect on the percent of sodium tubular transport (%TNa+), percent of chloride tubular transport (%TK+) and percent of potassium tubular transport (%TCl-). CTX and PLA2 reduced the GFR, while UF, PP and RVR remained stable during the full 120 min of perfusion. Crotoxin administration also diminished the %TK+ (control120 = 69.94 +/- 6.49; CTX120 = 33.28 +/- 4.78) and %TCl- (control120 = 79.53 +/- 2.67; CTX120 = 64.62 +/- 6.93). PLA2 reduced the %TK+, but exerted no effect on the %TNa+ or on that of TCl-. In conclusion, the C. d. collilineatus venom altered the renal functional parameters evaluated. We suggest that crotoxin and phospholipase A2 were involved in this process, since the renal effects observed would be due to the synergistic action of the components of the venom. 相似文献
69.
Sodium valproate is an anticonvulsant which elevates GABA levels in the brain. GABA interacts with dopamine functionally in certain areas of the brain involved in motor behavior such as the nucleus accumbens and the substantia nigra. In order to determine whether GABA can play a functional role in the pharmacological effects of valproate, both valproate and GABA were injected directly into these two brain areas and the effects of these compounds on motor function were studied. Both GABA and sodium valproate inhibited in a dose dependent manner the hyperactivity induced by the bilateral injection of dopamine into the nucleus accumbens. Picrotoxin, a GABA antagonist, blocked the inhibitory effect of valproate. When injected into the pars reticulata of the substantia nigra, both sodium valproate and GABA enhanced apomorphine-induced circling in rats with a unilateral lesion of lateral hypothalamus caused by 6-hydroxydopamine. This effect was blocked by the systemic administration of picrotoxin. These observations suggest that sodium valproate can produce effects that result from the activation of GABA receptor sites in the brain. 相似文献
70.